Taxane anticancer agents: A patent perspective

Expert Opinion on Therapeutic Patents

Volumn 26, Issue 1, 2016, Pages 1-20

  Ojima, Iwao ^a   Lichtenthal, Brendan ^a   Lee, Siyeon ^a   Wang, Changwei ^a   Wang, Xin ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Abraxane; Cabazitaxel; Cancer; Chemotherapy; Docetaxel; Drug combination; Formulation paclitaxel; Taxane; Taxoid

Indexed keywords

7 METHYLTHIOMETHYLPACLITAXEL; ALCOHOL; ANTINEOPLASTIC AGENT; CABAZITAXEL; CARBOPLATIN; CISPLATIN; CITRIC ACID; CREMOPHOR; DOCETAXEL; DOXORUBICIN; GANETESPIB; GEMCITABINE; LAROTAXEL; METHOTREXATE; MILATAXEL; MOTESANIB; NANOCARRIER; ORTATAXEL; PACLITAXEL; PACLITAXEL POLIGLUMEX; PERTUZUMAB; POLYGLUTAMIC ACID; POLYSORBATE 80; SB T 1214; SB T 1216; SB T 121602; SB T 12854; TAXANE DERIVATIVE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; NANOMATERIAL; TAXOID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CYTOTOXICITY; DRUG APPROVAL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HEAD AND NECK CANCER; HUMAN; IC50; KAPOSI SARCOMA; MEDIAN SURVIVAL TIME; MICELLE; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NANOEMULSION; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PARTICLE SIZE; PERSONALIZED MEDICINE; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSCRIPTION INITIATION; ANIMAL; DRUG DESIGN; FEMALE; MALE; NEOPLASMS; PATENT; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FEMALE; HUMANS; MALE; NANOSTRUCTURES; NEOPLASMS; PACLITAXEL; PATENTS AS TOPIC; TAXOIDS;

EID: 84955726721     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2016.1111872     Document Type: Review

References (163)

1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253-265.
2. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly invitro by taxol. Nature. 1979;277(5698):665-667.
3. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93:2325-2327.
4. Cragg GM, Kingston DGI, Newman DJ. Anticancer agents from natural products. Boca Raton (FL): CRC Press; 2012.
5. Bissery MC, Nohynek G, Sanderink GJ, et al. Docetaxel (Taxotere): A review of preclinical and clinical experience. Part I: preclinical experience. Anti-Cancer Drug. 1995;6(3):339-55, 363-8.
6. Gueritte F. General and recent aspects of the chemistry and structure-activity relationships of taxoids. Curr Pharm Design. 2001;7(13):1229-1249.
7. FDA. FDA approves new treatment for advanced head and neck cancer [Press Release]. [Internet]. 2006 [cited 2006 Oct 18]. Available from: http://www. Fda. gov/ NewsEvents/Newsroom/ PressAnnouncements/2006/ucm108771. htm
8. Goldstein LJ. MDR1 gene expression in solid tumours. Eur J Cancer. 1996;32A (6):1039-1050.
9. Mozzetti S, Ferlini C, Concolino P, et al. Class III ?-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res. 2005;11:298-305.
10. Darshan MS LM, Thadani-Mulero M, Levy BP, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71:6019-6029.
11. Giannakakou P, Plymate SR. Identifying taxane sensitivity in prostate cancer patients. WO2014047285A1. 2014.
12. de Leeuw RB-BL, Schiewer MJ, Ciment SJ, et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 2015;21:795-807.
13. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983;221(4617):1285-1288.
14. FDA. FDA labeling information-Javtana (cabazitaxel) [Internet]; 2010 [cited 2010 Jun]. Available from: http://www. Access data. Fda. gov/drugsatfda-docs/label/2010/ 201023lbl. pdf
15. Abidi A. Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. J Pharmacol Pharmacother. 2013;4(4):230-237.
16. Bissery MC, Bouchard H, Riou J, et al. Preclinical evaluation of TXD258, a new taxoid. Proc Am Assoc Cancer Res. 2000;41:214.
17. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15(2):723-730.
18. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: A randomised openlabel trial. Lancet. 2010;376(9747):1147-1154.
19. Galsky MD, Dritselis A, Kirkpatrick P, et al. Cabazitaxel. Nat Rev Drug Discov. 2010;9(9):677-678.
20. Mita AC, Figlin R, Mita MM. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clin Cancer Res. 2012;18(24):6574-6579.
21. Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i. V. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19 (9):1547-1552.
22. Feng L, Mumper RJ. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett. 2013;334(2):157-175.
23. He Z, Schulz A, Wan X, et al. Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation. J Control Release. 2015;20:867-875.
24. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317-1324.
25. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8(5):1038-1044.
26. Stinchcombe TE. Nanoparticle albuminbound paclitaxel: A novel cremphor-ELfree formulation of paclitaxel. Nanomedicine. 2007;2(4):415-423.
27. Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. Drug Des Devel Ther. 2012;6:371-384.
28. Benettaib B, Elias I, Renschler M, et al. Methods using pharmaceutical compositions comprising nanoparticles that comprise a taxane and an albumin for treatment of pediatric solid tumor. WO2014143613A1. 2014.
29. Desai NP, Soon-Shiong P. Use of nanoparticles comprising taxanes and albumin in combination with chemotherapeutic agents for treatment of pancreatic cancer. WO2011153010A1. 2011.
30. Yeo W, Wong N. Nanoparticles formulation comprising taxane and an albumin for treatment of hepatocellular carcinoma. WO2011119988A1. 2011.
31. Desai NP, Renschler M. Methods of treating melanoma comprising nanoparticles comprising taxane and a carrier protein. WO2014123612A1. 2014.
32. Desai NP, Trieu V. Combination therapy with thiocolchicine derivatives for treatment of proliferative disease such as cancer. WO2010105172A1. 2010.
33. Desai NP, Soon-Shiong P. Nanoparticle formulations comprising a taxane and an albumin in combination with other chemotherapeutic agents for the treatment of proliferative diseases such as cancer. WO2011156119A1. 2011.
34. FDA [Internet]. 2013. [cited 2013 Sep 6]. Available from: http://www. Fda. gov/ NewsEvents/Newsroom/ PressAnnouncements/ucm367442. htm
35. Sanofi [Internet]. 2010 [cited 2010 Aug 5]. Available from: http://www. news. sanofi. us/index. php?s=33507&item= 118530
36. Parente Duena A, Garces GJ, Mis Vizcaino R. Injectable taxane pharmaceutical composition. WO2010015400A2. 2010.
37. Tsai CJ, Jang SH, Huang T-M, et al. Stable pharmaceutical formulation of cabazitaxel. US20140171495 A1. 2014.
38. Torchilin VP. Multifunctional, stimulisensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13:813-827.
39. Zhang Q, Huang XE, Gao LL. A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. Biomed Pharmacother. 2009;63:603-607.
40. AAStocks [Internet]. 2015 [cited 2015 May 29]. http://www. Aastocks. com/en/ stocks/analysis/company-fundamental/? symbol=02186
41. Koudelka S, Turanek J. Liposomal paclitaxel formulations. J Control Release. 2012;163(3):322-334.
42. Crawford TC, Fetzer OS, Reiter LA, et al. Preparation of cyclodextrin-based polymers for therapeutic delivery as antitumor agents. US20120058971A1. 2012.
43. Desu HR, Patel KR, Pejaver SK, et al. Methods and compositions for delivery of taxanes in stable oil-in-water emulsions. US20110166214A1. 2011.
44. Vavia PR, Patel KDK. Amino acid surfactant based nanocarrier for drug targeting. IN2010MU02958A. 2014.
45. Li S-D, Ernsting MJ Cellulose-based nanoparticles for drug delivery for cancer treatment. WO2014015422A1. 2014.
46. Nabeta K. Non-aqueous taxane nanodispersion formulations and methods of using the same for treatment of proliferative diseases. US20140094509A1. 2014.
47. Zale SE, Troiano G, Ali MM, et al. Drug loaded polymeric nanoparticles and methods of making and using same. WO2010005721A2. 2010.
48. Seeney CE, Klostergaard J, Yuill WA, et al. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using. US20110130616A1. 2011.
49. Hoye TR, Wohl A, Macosko CW, et al. Silicate prodrugs and nanoparticles. WO2012166949A1. 2012.
50. Yin R, Pan J, Zhang Y, et al. Modified branched homopolymers forming aggregates with taxanes for nanoparticles. WO2014123791A1. 2014.
51. Karmali RA. Pharmaceutical compositions containing paclitaxel orotate. WO2012148494A2. 2012.
52. Beijnen JH, Schellens JHM, Moes J, et al. Solid pharmaceutical compositions comprising a taxane. WO2010020799A2. 2010.
53. Modi P. Oral formulations of chemotherapeutic agents. CA2843943A1. 2014.
54. Robert F, Harper K, Ackerman J, et al. A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naive patients with stage IIIB or stage IV non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;65(2):227-234.
55. Metzger-Filho O, Moulin C, De Azambuja E, et al. Larotaxel: broadening the road with new taxanes. Expert Opin Investig Drugs. 2009;18(8):1183-1189.
56. Dieras V, Viens P, Veyret C, et al. Larotaxel (L) in combination with trastuzumab in patients with HER2+ metastasis breast cancer (MBC): interim analysis of an open phase II label study. J Clin Oncol. 2008;26:1070.
57. Ojima I, Kamath A, Seitz JD. Taxol, taxoids and related taxanes. In: Hanessian S, editor. Natural products in medicinal chemistry. Weinheim (Germany): Wiley-VCH; 2013. p. 127-180.
58. Sternberg CN, Skoneczna IA, Castellano D, et al. Larotaxel with cisplatin in the first-line treatment of locally advanced/ metastatic urothelial tract or bladder cancer: A randomized, active-controlled, phase III trial (CILAB). Oncology. 2013;85 (4):208-215.
59. Beer M, Lenaz L, Amadori D. Phase II study of ortataxel in taxane-resistant breast cancer. J Clin Oncol. 2008;26:1066.
60. ClinicalTrials. gov. An Efficacy Study Of Ortataxel In Recurrent Glioblastoma [Internet]. 2013 [cited 2013 Oct 23]. Available from: https://clinicaltrials. gov/ ct2/show/NCT01989884
61. Moore M, Jones C, Harker G, et al. Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer. J Clin Oncol. 2006;24:3591.
62. Roche M, Kyriakou H, Seiden M. Drug evaluation: Tesetaxel-an oral semisynthetic taxane derivative. Curr Opin Investig Drugs. 2006;7(12):1092-1099.
63. Beeram M, Papadopoulos K, Pantnaik A, et al. Phase I dose-ranging, pharmacokinetic (PK) study of tesetaxel, a novel orally active tubulin-binding agent. J Clin Oncol. 2010;28:13075.
64. Ramanathan RK, Picus J, Raftopoulos H, et al. A phase II study of milataxel: A novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008;61 (3):453-458.
65. Camps C, Felip E, Sanchez JM, et al., on behalf of Spanish Lung Cancer Group. Phase II trial of the novel taxane BMS-184476 as second-line in nonsmall-cell lung cancer. Ann Oncol. 2005;16:4597-601.
66. Bradley MO, Webb NL, Anthony FH, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res. 2001;7(10):3229-3238.
67. Bedikian AY, DeConti RC, Conry R, et al. Phase 3 study of docosahexaenoic acidpaclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol. 2011;22(4):787-793.
68. Bradley MO, Swindell CS, Anthony FH, et al. Tumor targeting by conjugation of DHA to paclitaxel. J Control Release. 2001;74(1-3):233-236.
69. Paz-Ares L, Ross H, O'Brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008;98(10):1608-1613.
70. Jeyapalan SA, G. M, D. J. A phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), and radiation (RT) for newly diagnosed high-grade gliomas. J Clin Oncol. 2011;29(suppl):2036.
71. Dipetrillo T, Suntharalingam M, Ng T, et al. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: A phase 2 trial. Am J Clin Oncol. 2012;35(1):64-67.
72. Markman M. Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf. 2003;2 (2):141-146.
73. Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer. 2004;11(1):82-85.
74. FDA [Internet]. 2012 [cited 2012 Jun 8]. Available from: http://www. Fda. gov/ NewsEvents/Newsroom/ PressAnnouncements/ucm307549. htm
75. MPR [Internet]. 2013 [cited 2013 Sep 12]. Available from: http://www. Empr. com/drugs-in-the-pipeline/fda-fast-tracksganetespib-for-non-small-cell-lung-adeno carcinoma/article/311445/
76. Ramalingam SS, Goss GD, Andric ZG, et al. A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1). J Clin Oncol. 2013;31(18):CRA8007.
77. NIH [Internet]. 2013 [cited 2013 Feb 4]. Available from: https://www. clinicaltrials. gov/ct2/show/NCT01798485
78. Hei Y-J, Yao B. Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset of Asian patients. WO2012142325A1. 2012.
79. Conlin AK, Seidman AD, Bach A, et al. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2010;10(4):281-287.
80. Desai NP, Tao C, De T, et al. Nanoparticle formulations comprising taxane derivatives for cancer treatment. WO2010118365A1. 2010.
81. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-1703.
82. Desai NP, Soon-Shiong P. Nanoparticle formulations comprising a taxane and an albumin in combination with other chemotherapeutic agents for treatment of cancer. WO2011123393A1. 2011.
83. Vukovic V. Specific cancer treatment regimens with ganetespib. WO2014189937A1. 2014.
84. NIH [Internet]. 2015 [cited 2015 Jun 15]. Available from: https://www. clinicaltrials. gov/ct2/show/study/NCT01962948? term=paclitaxel+and+ganetespib&rank=1
85. Mahammedi H, Planchat H, Cure H, et al. Pilot phase II study with docetaxel in combination with curcuminoids in patients with hormone-resistant prostate cancer (HRPC). J Clin Oncol. 2011;29. suppl;abstr e15069.
86. Barthomeuf C, Chollet P, Cure H, et al. Methods and pharmaceutical compositions for the treatment of hormone-refractory prostate cancers. WO2012146706A1. 2012.
87. Duksin C, Tessler S. Methods for treating non-small cell lung cancer using combination of taxanes, an anti-clusterin oligonucleotide and platinum-based chemotherapeutic agents. WO2012156817A2. 2012.
88. Kubota K, Ichinose Y, Scagliotti G, et al. Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis. Ann Oncol. 2014;25(2):529-536.
89. Bahleda R, Sessa C, Del Conte G, et al. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. Invest New Drugs. 2014;32 (6):1188-1196.
90. Cohen P, Oprea IC. An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative WO2011158206A1. 2011.
91. Gupta S. Novel antitumoral use of cabazitaxel in metastatic prostate cancer. WO2011051894A1. 2011.
92. Patel PH, Peterson AC. Anti-c-Met antibodies and taxanes combined with anti-VEGR antibodies for treatment of ER-/ PR-/HER-metastatic breast cancer. US20110287003A1. 2011.
93. Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebocontrolled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2012;30(4):362-371.
94. Weinreich DM. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane WO2011038139A1. 2011.
95. Desai NP, Soon-Shiong P. Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer. US20100112077A1. 2010.
96. Somer BG, Schwartzberg LS, Arena FP, et al. Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). J Clin Oncol. 2007;25:18.
97. Swain SM, Kim SB, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461-471.
98. McCormack PL. Pertuzumab: A review of its use for first-line combination treatment of HER2-positive metastatic breast cancer. Drugs. 2013;73(13):1491-1502.
99. Baselga J, Manikhas A, Cortes J, et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol. 2014;25(3):592-598.
100. Rozencweig M, Goldfarb RH, Forenza S. Non-pegylated liposomal doxorubicin triple combination therapy. US8026267B2. 2011.
101. Robert N, Krekow L, Stokoe C, et al. Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with earlystage breast cancer: A pilot study. Breast Cancer Res Treat. 2011;125(1):115-120.
102. Desai NP, Soon-Shiong P. Use of nanoparticles comprising taxanes and albumin in combination with chemotherapeutic agents for the treatment of bladder cancer. WO2011153009A1. 2011.
103. Smith DC, Grivas P, Daignault S, et al. A phase II trial of neoadjuvant ABI-007, carboplatin, and gemcitabine (ACG) in patients with locally advanced carcinoma of the bladder. J Clin Oncol. 2011;29. suppl 7;abstr 244.
104. Chirgwin J, Chua SL. Management of breast cancer with nanoparticle albuminbound (nab)-paclitaxel combination regimens: A clinical review. Breast J. 2011;20:5.
105. Lianos GD, Vlachos K, Zoras O, et al. Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. Onco Targets Ther. 2014;7:491-500.
106. Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligandtargeted cancer therapeutics and imaging agents. Nat Rev Drug Discov. 2015;14:203-219.
107. Castaigne J-P, Demeule M, Lawrence B. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog. WO2010121379A1. 2010.
108. Demeule M, Regina A, Che C, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther. 2008;324(3):1064-1072.
109. Bertrand Y, Currie JC, Demeule M, et al. Transport characteristics of a novel peptide platform for CNS therapeutics. J Cell Mol Med. 2010;14(12):2827-2839.
110. Bowen BC, Bradley WG. Amyotrophic lateral sclerosis: The search for a spectroscopic marker of upper motoneuron involvement. Arch Neurol. 2001;58 (5):714-716.
111. Ojima I, Chen J, Sun L, et al. Design, synthesis, and biological evaluation of new-generation taxoids. J Med Chem. 2008;51(11):3203-3221.
112. Ojima I, Das M. Recent advances in the chemistry and biology of new generation taxoids. J Nat Prod. 2009;72(3):554-565.
113. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nature Rev Drug Discov. 2007;6:115-120.
114. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267-284.
115. Botchkina GI, Zuniga ES, Das M, et al. New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheriods induced by purified colon tumor-initiating cells. Mol Cancer. 2010;9:192-204.
116. Zuniga ES. Design, synthesis and biological evaluation of new-generation taxoidbased tumor-targeting drug conjugates [Ph. D. Thesis]. Stony Brook University; 2012.
117. Kuznetsova L, Sun L, Chen J, et al. Synthesis and biological evaluation of novel 3?-difluorovinyl taxoids. J Fluorine Chem. 2012;143:177-188.
118. Otova B, Ojima I, Vaclavikova R, et al. Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes. Invest New Drugs. 2012;30 (3):991-1002.
119. Ojima I. Taxoid-Fatty Acid Conjugates and Pharmaceutical Compositions Thereof. US7820839B2. 2010.
120. Seitz J, Ojima I. Drug conjugates with polyunsaturated fatty acids. In: Kratz F, Senter P, Steinhagen H, editors. Drug delivery in oncology-from research concepts to cancer therapy. Vol. 3. Weinheim (Germany): Wiley-VCH; 2011. p. 1323-1360.
121. Jing Y-R, Zhou W, Li W-L, et al. The synthesis of novel taxoids for oral administration. Bioorg Med Chem. 2014;22:194-203.
122. McChesney JD, Venkataraman S, Henri JT. Preparation of taxane analogues for the treatment of cancer and neurodegenerative disorders. WO2011028571A1. 2011.
123. McChesney JD, Henri JT, Venkataraman SK, et al. Taxane and abeo-taxane analogs as antitumor agents. WO2013106029A1. 2013.
124. Kozlowski A, Riley TA, McManus SP. Preparation of deuterated and/or fluorinated taxane derivatives. WO2012088433A1. 2012.
125. Chari RVJ. Potent cell-binding agent drug conjugates. WO2009134870A1. 2009.
126. Chari RVJ. Potent cell-binding agent drug conjugates. US20100092495A1. 2010.
127. Liu J, King D. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal cysteine-containing extensions. WO2009026274A1. 2009.
128. Hamada H, Mikuni K, Nakanishi K, et al. Antitumor compositions containing taxoid derivatives covalently linked to tumorspecific antibody. US20070025995A1. 2007.
129. Gastaldi D, Zonari D, Dosio F. Targeted taxane delivery systems: recent advances. Drug Deliv Lett. 2011;1(2):105-117.
130. Klostergaard J, Farquhar D, Ghosh SC, et al. Anticancer agent-hyaluronic acid conjugate compositions and methods of use. WO2008134528A1. 2008.
131. Maneval DC, Shepard HM, Thompson CB. Protein sequences of human hyaluronidase and combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane. WO2013151774A1. 2013.
132. Fazioni S, Hovda K, Livi V, et al. Method for determining the amount of conjugated taxane in poly(glutamic acid)-taxane conjugates. WO2008107174A1. 2008.
133. Bai H, Tsang KY, Jin Y, et al. Large scale process for preparing poly(glutamyl-glutamate) conjugates for anticancer drug delivery. WO2014175898A1. 2014.
134. Kozlowski A, Riley TA, McManus SP. Multi-arm polymeric prodrug conjugates of taxane-based compounds as a drug delivery systems. WO2012088422A1. 2012.
135. Scripture CD, Figg WD, Sparreboom A. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol. 2006;4 (2):165-172.
136. Mutz MW, Webb R III, Gestwicki JE. Therapeutic agents having reduced toxicity. WO2011130317A2. 2011.
137. Sengupta S, Kulkarni A, Rao P, et al. Compositions of a chemotherapeutic agent-cholesterol conjugate for treating cancer and methods for making the same. WO2013188763A1. 2013.
138. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev. 2004;56:1127-1141.
139. Vlahov IR, Leamon CP. Engineering folate?drug conjugates to target cancer: from chemistry to clinic. Bioconjug Chem. 2012;23:1357-1369.
140. Russell-Jones G, McTavish K, McEwan J, et al. Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem. 2004;98:1625-1633.
141. Chen SY, Zhao XR, Chen JY, et al. Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjugate Chem. 2010;21 (5):979-987.
142. Ojima I, Zuniga ES, Berger WT, et al. Tumor-targeting drug delivery of new generation taxoids. Future Med Chem. 2012;4:33-50.
143. Ojima I. Drug Conjugates with heterobifunctional linkers. US 7, 847, 119 B2. 2010.
144. Chen J, Chen S, Zhao X, et al. Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. J Am Chem Soc. 2008;130:16778-16785.
145. Vineberg JG. Design, synthesis, and biological evaluation of novel taxoid-based drug conjugates and theranostic imaging agents towards tumor-targeted chemotherapy [Ph. D. Thesis]. Stony Brook University; 2014.
146. Rayan A. Conjugate of a taxane and biotin and uses thereof. WO2014191989A1. 2014.
147. Gebhard JR, Vollmer D, Patel D, et al. Cobalamin taxane bioconjugates useful as oral anti-cancer or anti-angiogenic drugs. WO2008115805A2. 2008.
148. Gebhard JR, Patel D. Cobalamin taxane bioconjugates for treating eye disease. WO2010088287A1. 2010.
149. Gebhard JR, Patel D. Taxane compounds for treating eye disease. US20100016256A1. 2010.
150. Seitz JD, Vineberg JG, Herlihy E, et al. Design, synthesis and biological evaluation of a highly-potent and cancer cell selective folate-taxoid conjugate. Bioorg Med Chem. 2015;23(9):2187-2194.
151. Armstrong RC, Wierenga WD. Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment WO2010105016A1. 2010.
152. Hart CP, Sun JD, Elenbaas BA, et al. Treatment of pancreatic cancer with a combination of a hypoxia-activated prodrug and a taxane. WO2015013448A1. 2015.
153. Chakravarty A, Ecsedy JA, Kleinfield RW, et al. Methods of treating cancer using aurora kinase inhibitors. WO2013142491A1. 2013.
154. Hancox UJ, Cosulich S, Davies BR. Combination treatment of cancer comprising 8-[(1R)-1-(3, 5-difluorophenylamino) ethyl]-N, N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide and a taxane. WO2014135851 A1. 2014.
155. Liu L, Gerson S. O6-methylguanine methyltransferase (MGMT) inhibitor in combination with other chemotherapeutic agents for the treatment of neoplastic disorders. US8791081B2. 2014.
156. Wengner AM, Siemeister G. Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer. WO2014198776A1. 2014.
157. Robertson FM. Combination therapy comprising paclitaxel and romidepsin for treating an inflammatory breast cancer. WO2013085902A1. 2013.
158. Davies BR. Pharmaceutical combination comprising AZD5363 and taxanes for treatment of cancer. WO2012131399A1. 2012.
159. Ulivi P, Arienti C, Zoli W, et al. In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. Curr Cancer Drug Targets. 2010;10:600-610.
160. Fodstad O. B7-H3 antagonists and taxanes for treating cancer. WO2012004410A1. 2012.
161. Blackman RK, Foley KP, Proia D. Combination therapy using with taxanes and triazolone HSP90 inhibitory compounds for treatment of cancer. WO2011049946A1. 2011.
162. Patel L, Williams S, Wilding I, et al. Combination therapy comprising a taxane and a sigma receptor ligand such as rimcazole. WO2010128309A1. 2010.
163. Shankar G, Bentzien F, Lamb P, et al. Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents for the treatment of cancer. WO2010045601A2. 2010.